Effect of Interscalene Block on Ventilatory Function

NCT ID: NCT01740453

Last Updated: 2015-01-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Interscalene block with local anesthetic impairs ventilation (unilateral diaphragmatic dysfunction). Single injection of local anesthetic induced transitory dysfunction (\< 24h). The investigators hypothesized that continuous interscalene block would prolonged ventilatory impairment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Unilateral pulmonary dysfunction occured after interscalene block due to phrenic nerve paralysis. This reduction induced vital capacity alteration and peek flow reduction.Several studies analysed dysfunction recovery duration after single injection using short (lidocaine)or intermediate (ropivacaine, bupivacaine)local anesthetic drug. Because continuous infusion prolonged block duration, phenic nerve may be also prolonged. However no study with continuous interscalene infusion have been performed for this dysfunction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Depression Anesthesia Morbidity Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single (no catheter)

ropivacaine single injection : 5 mg/ml 15 ml

Group Type NO_INTERVENTION

No interventions assigned to this group

Continuous infusion

Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h

Group Type EXPERIMENTAL

ropivacaine 2 mg/ml

Intervention Type DRUG

single

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ropivacaine 2 mg/ml

single

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* surgery : scheduled for elective shoulder surgery
* available for 1 month of follow up
* physical status : 1, 2, 3

Exclusion Criteria

* body mass index \> 35
* contraindication for interscalene block (local sepsis, bleeding, allergy, peripheral neuropathy)
* vital capacity less than 1.5 liters
* cardiac or renal insufficiency
* physical status \>3, pregnant, weigh less than 50 kg
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pierre and Marie Curie University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Philippe Cuvillon

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe Cuvillon, Md,PhD

Role: PRINCIPAL_INVESTIGATOR

Caremeau Hospital, Nimes, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre hospitalier La Pitié Salpetriere

Paris, Île-de-France Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KTBIS-2012-V1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.